Akili is developing video game-based digital medicine to improve cognitive function. The company uses features of the tech and entertainment industries to develop it's digital treatment and address inattention in children with attention deficit hyperactivity disorder.

Register for Details

For more details on financing and valuation of private companies similar to Akili before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Akili

To invest in Akili pre-IPO

Can you invest in Akili pre-IPO?

You may invest in Akili as it is a public company listed on the NASDAQ with ticker AKLI. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Akili before it goes public?

You can no longer sell shares of Akili on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Akili shares?

Forge can no longer determine the value of Akili shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Akili a publicly traded company?

Akili became a public company following its SPAC on 08/22/2022 and is now traded on the NASDAQ under the ticker AKLI.

To learn more about Akili potential IPO

Will Akili go IPO?

Akili became a public company following its SPAC on 08/22/2022 and is now traded on the NASDAQ under the ticker AKLI.

What is Akili’s IPO price?

The IPO price of Akili is not currently available.

When was Akili founded?

Akili was founded in 2011.

What is Akili funding to date?

Akili has raised $275.08MM to date.

Who are Akili’s major investors?

Akili Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
05/26/2021 Series D $151.68MM $xx.xx $45.23B Amgen Ventures, Baillie Gifford, Dave Baszucki, Evidity Health Capital, Fearless Ventures, Jazz Venture Partners, Ladera Venture Partners, Mirae Assets, M Ventures, Neuberger Berman Funds, New Leaf Venture Partners, Omidyar Technology Ventures, Polaris Partners, Quad Investment Management, Shionogi & Co Ltd, Temasek
Price per Share
$xx.xx
Shares Outstanding
18,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.0x
Dividend Rate
10.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Amgen Ventures, Baillie Gifford, Dave Baszucki, Evidity Health Capital, Fearless Ventures, Jazz Venture Partners, Ladera Venture Partners, Mirae Assets, M Ventures, Neuberger Berman Funds, New Leaf Venture Partners, Omidyar Technology Ventures, Polaris Partners, Quad Investment Management, Shionogi & Co Ltd, Temasek
05/09/2018 Series C $68.2MM $xx.xx $25.94B Amgen Ventures, Canepa Advanced Healthcare Fund Brooklands Capital Strategies, Clsa, Digital Garage Group, Fearless Ventures, Jazz Venture Partners, M Ventures, Omidyar Technology Ventures, Temasek
Price per Share
$xx.xx
Shares Outstanding
8,016,645
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Canepa Advanced Healthcare Fund Brooklands Capital Strategies, Clsa, Digital Garage Group, Fearless Ventures, Jazz Venture Partners, M Ventures, Omidyar Technology Ventures, Temasek
07/20/2016 Series B $42.36MM $xx.xx $11.37B Amgen Ventures, M Ventures
Price per Share
$xx.xx
Shares Outstanding
7,341,485
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, M Ventures
02/19/2012 Series A-1 $4MM $xx.xx $2.8B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
02/19/2012 Series A-2 $8.83MM $xx.xx $2.8B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
4,427,072
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
Updated on: Nov 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.